Bioavailability and bioequivalence conference is a platform to have all the scientific eminent across the globe. In pharmacology, bioavailability (BA) is a subcategory of ingestion and is the part of a managed measurement of unaltered medication that achieves the systemic flow, one of the important pharmacokinetic properties of medications. Bioavailability is one of the crucial apparatuses in pharmacokinetics, as bioavailability must be considered when computing doses for non-intravenous courses of organization.

Biologic & Biosimilar conference is a platform to have all the scientific eminent across the globe. The bio similar segment is one of the fastest growing segments and is likely to reach more than USD 25 billion by 2020.  Despite high development costs, the bio similar segment is likely to witness rapid growth due to the rising number of off-patent biologic drugs. The growth of this sector is attributed to the positive outcomes of on-going clinical trials and the growing demand for bio similar in different therapeutic applications. The application of advanced technologies such as recombinant DNA technology, genetic engineering, and combinatorial chemistry has increased the entry of novel biopharmaceuticals in the market which will contribute to this segment’s growth over the next four years.

Human pharmacokinetic conference is a platform to have all the scientific eminent across the globe. Human pharmacokinetic in vivo studies are often presumed to serve as the “gold standard” to assess product bioequivalence (BE) of immediate-release (IR) solid oral dosage forms. However, when this general assumption is re-visited, it appears that in vitro studies are sometimes better than in vivo studies in assessing BE of IR solid oral dosage forms. Reduced costs are achieved through avoiding in vivo studies where BE is self-evident, where biopharmaceutical data anticipates BE, and where in vivo BE study type II error is high. Sponsors of potential in vivo human pharmacokinetic BE testing should be required to justify why in vitro data is insufficient, similar to proposed animal testing requires justification to not employ an in vitro approach.

Drug product conference performance is a vital aspect of drug development as it draws on interdisciplinary expertise from both pharmaceutics and pharmacokinetics disciplines. It is at the key interface that the discipline of bio pharmaceutics has emerged. The past two decades have witnessed considerable advances in bio pharmaceutics particularly with regard to bioavailability and bioequivalence, as they relate to product quality and regulatory standards of approval.

Pharmacodynamics and pharmacokinetics conference is a platform to have all the scientific eminent across the globe. Pharmacodynamics and pharmacokinetics are the two principal areas of pharmacology. Pharmacodynamics is the study of the molecular, biochemical, and physiological effects of drugs on cellular systems and their mechanisms of action.